It is unclear whether anxiety increases or decreases suicidal risk. This may contribute to the lack of guidance on which antidepressant medications are best for suicidal depressed patients who present with high anxiety. This study explored whether anxiety predicts suicidal ideation in depressed individuals treated with paroxetine or bupropion. An 8-week double-blind trial comparing controlled-release paroxetine (N = 36) versus extended-release bupropion (N = 38) for effect on suicidal ideation and behavior in depressed patients with suicidal ideation, past attempt, or both found an advantage for paroxetine, but anxiety effects were not investigated. This secondary analysis explored the relationship, measured at baseline and weekly, of anxiety with suicidal ideation. Anxiety severity measured weekly correlated with suicidal ideation severity irrespective of treatment (P = 0.012). Patients with high baseline anxiety showed a trend toward faster reduction of suicidal ideation with paroxetine compared with bupropion treatment (standard P = 0.047; bootstrap P = 0.077). The latter finding, if confirmed in larger samples, could enhance choice of antidepressant medication for suicidal, depressed patients presenting with high levels of anxiety. Int Clin Psychopharmacol 33:249-254
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Introduction
There is a lack of evidence to guide pharmacotherapy for suicidal depressed patients. One frequent clinical challenge is how best to manage anxiety in suicidal patients as its effect on suicide risk is controversial (Oquendo et al., 1997; Brown et al., 2000; Placidi et al., 2000; Sareen et al., 2005a Sareen et al., , 2005b Sokero et al., 2005; Bolton et al., 2007; Nakagawa et al., 2008; Nock et al., 2010) . There is a lack of consensus as to whether anxiety is a risk factor for suicide attempts (Sokero et al., 2005) or deaths (Brown et al., 2000) . Some studies found that anxiety symptoms and disorders predict suicidal ideation, attempts, and death, even adjusting for sociodemographic variables and psychiatric comorbidity (Fawcett et al., 1990; Sareen et al., 2005a Sareen et al., , 2005b Bolton et al., 2007; Nock et al., 2010) . Other studies found no association or an inverse one between anxiety and suicidal ideation or behavior (Placidi et al., 2000; Grunebaum et al., 2005) .
This knowledge gap is important because depression, the most frequent cause of suicidal ideation and behavior, and anxiety disorders are common and have a lifetime comorbidity estimated at almost 60% (Mineka et al., 1998) . Anxious depressed individuals experience greater distress (Roy-Byrne et al., 2000; Papakostas and Larsen, 2011; Seo et al., 2011) and have worse outcomes with antidepressant treatment in terms of symptom relief, adverse effects, and serious adverse events (Fava et al., 2008) , particularly in treatment-resistant depression (Wu et al., 2013; De Carlo et al., 2016) . Cross-sectional data suggest that lifetime suicidal ideation and behavior are more common in people with anxious depression (Fawcett et al., 1990; Seo et al., 2011) . A recent meta-analysis found that anxiety symptoms and the presence of an anxiety diagnosis predicted subsequent suicidal ideation and attempt, though not suicide death, but the effect sizes were small (odds ratio = 1.39-1.64). The authors suggested that limitations of existing research, such as how comorbidity or time-course is analyzed, may obscure clinically relevant associations between anxiety and suicidal ideation or behavior (Bentley et al., 2016) .
Serotonergic antidepressants appear to be efficacious for anxious depression and anxiety disorders in contrast to noradrenergic antidepressants (Baldwin et al., 2005; Fava et al., 2007; Papakostas et al., 2008) . In our trial comparing the selective serotonin reuptake inhibitor (SSRI) paroxetine (N = 36) with the norepinephrine-dopamine reuptake inhibitor bupropion (N = 38), in depressed suicide ideators or attempters, we found that patients with more severe suicidal ideation experienced greater reduction in suicidal ideation with paroxetine. No main effect of treatment on time to first suicide attempt was found . However, potential moderation of treatment effects by baseline anxiety was not explored .
We used data from the aforementioned trial to explore the effect of baseline anxiety symptoms in suicidal depression in terms of response to treatment of suicidal ideation. Our primary interest was the effect of baseline anxiety, a meaningful characteristic because it may guide clinicians in medication selection when initiating treatment. We hypothesized that higher baseline anxiety would predict greater reduction in suicidal ideation with paroxetine compared with bupropion treatment. Secondarily, we examined anxiety across the 8-week trial to explore its longitudinal relationship with suicidal ideation. We predicted that decreased anxiety measured weekly would be associated with reduction in suicidal ideation over the 8 weeks.
Methods

Patients
Methods and initial results have been reported . This 8-week randomized clinical trial (RCT) enrolled patients (N = 74) with a current episode of Diagnostic and Statistical Manual of Mental Disorders, 4th ed., major depressive disorder who scored at least 16 on the Hamilton Depression Rating Scale (HDRS-17; Hamilton, 1960) . Eligibility also required a history of a suicide attempt or score at screening evaluation of more than or equal to 2 (wishes to be dead or has any thoughts of possible death to self) on the HDRS suicide item, or both. Exclusion criteria were as follows: bipolar disorder, psychosis, drug or alcohol dependence within 6 months, and unstable medical or neurological illness. The study was approved by the Institutional Review Board at the New York State Psychiatric Institute and was conducted in compliance with the standards established in the Declaration of Helsinki. After complete study description, written informed consent was obtained from all participants. After baseline assessments, participants were randomized 1 : 1 to 8-week treatment with controlled-release oral paroxetine (N = 36) or extended-release bupropion (N = 38). Participants met weekly with a research psychiatrist for medication management and a psychologist for research ratings. Dosing began at 25-mg paroxetine or 150-mg bupropion daily, increasing in standardized increments to 50 or 450 mg, respectively. Participants, psychiatrists, and raters were blind to treatment. Baseline clinical and demographic variables are summarized in Table 1 (for additional variables see Grunebaum et al., 2012) . Treatment groups did not differ in demographic characteristics, comorbid cluster B, lifetime substance use disorders, or history of prior suicide attempts .
Outcome and measures
Clinical assessors were masters or doctoral-level psychologists. Inter-rater reliability was high (ICC HDRS-17 = 94%, ICC SSI = 97%) and maintained through weekly consensus conferences and videotapes. The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 4th ed., (SCID-I and II) was used to diagnose axis I and axis II disorders (First et al., 1996; First et al., 2002) . Depressive symptoms were measured using the HDRS-24. The Columbia Suicide History Form (Oquendo et al., 2003) was used to classify suicidal events. The clinician-rated Beck Scale for Suicidal Ideation (SSI; Beck et al., 1979) was used to measure frequency and intensity of suicidal ideation at baseline and weekly. As this exploratory analysis was not pre-planned, the study did not include a specific anxiety scale. To measure anxiety, we used an anxiety symptom cluster extracted through a factor analysis of the HDRS-24, in which we used a polychoric correlation method that corrects for the limited range of rating scale responses (Grunebaum et al., 2005; Keilp et al., 2012) . The anxiety cluster comprises HDRS items assessing agitation, psychic anxiety, somatic anxiety, and hypochondriasis, and in this, the sample at baseline had a range of 0-9, mean = 3.9 (SD = 2.1; median = 4), and a normal distribution.
Statistical methods
The outcome of interest was SSI score during weeks 1-8 (baseline SSI was excluded from the outcome). Generalized least squares regression for correlated longitudinal data was used to model SSI score across the 8 weeks for each patient and compare between treatment groups (Pinheiro and Bates, 2000) . Because we expected the rate of change of suicidal ideation to decrease with time, we used a natural log transformation of time. To test our hypothesis that baseline anxiety would moderate the effect of treatment group on SSI score, we first tested a full model with main effects of treatment, natural log(time), baseline inpatient status, past suicide attempt (yes/no), baseline SSI, baseline anxiety, the three-way interaction of treatment × ln(time) × baseline anxiety, and the associated two-way interactions. We then tested a reduced model with only the variables essential to the research question, with main effects of baseline SSI, baseline anxiety, treatment, and the interaction of baseline anxiety × treatment.
We fitted regressions comparing nine different correlation structures, and the best, ARMA(1,1), was used based on the smallest value of the Bayes Information Criterion. We checked for data collinearity following the guideline that the variance inflation factor (VIF) should not exceed 10 ( Kleinbaum et al., 2008) . To compute P values that allow for collinearity, we performed bootstrap calculations (Efron and Tibshirani, 1993) with B = 10 000 resamples, keeping each patient's time points together. To illustrate the effect of baseline anxiety on differential treatment response, we used the model fitted to the full sample to estimate the mean difference in suicidal ideation between treatment groups for patients at the median (score = 7) of the highest quartile of baseline anxiety. As a check, we bootstrapped this analysis using the full study sample.
To explore the longitudinal relationship of anxiety with suicidal ideation, we fitted the aforementioned reduced regression model, substituting anxiety measured weekly instead of the baseline anxiety × treatment interaction term, and also tested for an interaction of weekly anxiety with treatment. All statistical tests were two-sided and used SPSS version 23 (IBM, Armonk, New York, USA) or R software version 3.3.2 (R Core Team, Vienna, Austria).
Results
Baseline anxiety
Baseline anxiety did not differ between treatment groups (t = − 3.78, d.f. = 72, P = 0.706). Patients with higher baseline anxiety (median split) and allocated to bupropion had higher SSI scores at baseline compared with those allocated to paroxetine (t = − 2.31, d.f. = 40, P = 0.026), but as noted before, all models adjusted for baseline SSI. There was evidence of collinearity with the full model (VIF = 23.47), but not the reduced model (VIF = 5.25), which also had a lower (better) Bayes Information Criterion value of 2921. The reduced (best) model showed a significant interaction of baseline anxiety with treatment, such that patients with high baseline anxiety experienced a greater reduction in suicidal ideation on paroxetine compared with bupropion (t = − 2.03, P = 0.047) ( Table 2 ). The bootstrapped P value was at a trend level of statistical significance (P = 0.077). The model of differential treatment effect in the subgroup with baseline anxiety in the highest quartile (n = 17) predicted 4.36 (SE = 1.71) points lower suicidal ideation, on average, with paroxetine compared with bupropion treatment (P = 0.010). In the full study sample, the bootstrap showed P = 0.055. Figure 1 illustrates mean SSI score by treatment group for patients who presented with baseline anxiety in the highest quartile (n = 17).
Longitudinal anxiety
Adjusting for baseline anxiety and baseline SSI, anxiety assessed weekly was associated with weekly suicidal ideation severity [estimate = 0.32 (95% confidence interval: 0.07-0.57), d.f. = 472.31, t = 2.54, P = 0.012] (Table 3 ). An interaction term for weekly anxiety × treatment group was not significant (P = 0.53), indicating that the longitudinal correlation of anxiety with SSI score was not different between treatment groups.
Discussion
In this post-hoc analysis of a randomized antidepressant trial in suicide ideators and attempters with major depressive disorder, we found that individuals presenting with high anxiety at baseline had less severe suicidal ideation over time with paroxetine compared with Beck Scale of Suicidal Ideation mean score by study week in suicidal, depressed patients at highest quartile of baseline HDRS anxiety factor randomized to controlled-release paroxetine or extended-release bupropion. Predicted difference in SSI score between groups = 4.36 (SE = 1.71) points lower, on average, with paroxetine compared to bupropion (assumes baseline HDRS Anxiety factor at highest quartile median = 7; P = 0.010; bootstrapped P = 0.055; based on fitted reduced model using all subjects' data). Error bars are SEM. HDRS, Hamilton Depression Rating Scale; SSI, Scale for Suicidal Ideation.
Anxiety, suicidal ideation and treatment Parris et al. 251
bupropion treatment. This moderating effect on treatment was at the trend-level of statistical significance in a rigorous bootstrap analysis. Anxiety assessed longitudinally was significantly associated with suicidal ideation severity irrespective of treatment group.
Best pharmacotherapeutic practices for depressed, suicidal patients with high anxiety -a relatively frequent clinical scenario -are uncertain. There are few, if any, reliable moderators of antidepressant treatment to guide initial medication choice for patients based upon clinical presentation. Increased anxiety or agitation during the initial days of antidepressant pharmacotherapy has been cited as a possible risk factor for suicidal behavior, and patients with anxious depression may be at greater risk (Sinclair et al., 2009) . A recent, patient-level analysis of placebocontrolled SSRI trials (N = 8262) found that SSRI-treated patients were more likely to report increased somatic anxiety, but less likely to experience increased psychic anxiety or psychomotor agitation during the first treatment week compared with placebo (Naslund et al., 2017) . Our post-hoc analysis results are partially consistent with the latter study in that patients with the highest levels of baseline anxiety experienced a greater decrease in suicidal ideation during the initial weeks of treatment with paroxetine compared with bupropion, suggesting a possible early, anxiolytic SSRI effect.
Anxiety and suicidal ideation are linked theoretically and biologically. Both may partly involve avoidant reactions to aversive emotions and self-appraisals (Baumeister, 1990; Barlow et al., 2014) . Reducing anxiety may help relieve a desire to escape by suicide. Serotonin hypofunction is implicated in both anxiety and suicide. Suicide decedents and attempters show lower cerebrospinal fluid levels of 5-hydroxyindoleacetic acid, serotonin's main metabolite, fewer serotonin transporter sites in numerous brain regions, and upregulation of post-synaptic 5-HT 1A and 5-HT 2A serotonin receptors in ventral prefrontal cortex (Mann, 2003) . The efficacy of SSRIs in treating a number of anxiety disorders indicates a role of serotonin dysfunction in anxiety as well (Kent et al., 1998 Weisstaub et al., 2006; Sullivan et al., 2013; Coplan et al., 2014) . Thus, paroxetine's modulation of serotonin functioning may be specifically beneficial for suicidal depressed individuals who present with high anxiety.
Nonetheless, studies on the differential effects of SSRIs versus other antidepressants for anxious versus nonanxious depression have been inconclusive (Rush et al., 2001; Fava et al., 2008) Serotonin-norepinephrine reuptake inhibitors (Papakostas and Larsen, 2011) and tricyclic antidepressants (Uher et al., 2011) have demonstrated efficacy comparable to SSRIs for depression, but effects on suicidal ideation were not reported. Bupropion is generally avoided in the management of anxiety disorders and anxious depression, because of its potential to exacerbate anxiety and lack of efficacy for panic attacks (Preskorm, 1995) , though this concern is debatable (Stahl et al., 2004; Fava et al., 2005; Zimmerman et al., 2005) . In contrast to SSRIs, bupropion is not approved by the Federal Drug Administration for the treatment of anxiety disorders. Nonetheless, trials of SSRIs versus bupropion have yielded equivocal results for differential effects on depression or anxiety symptoms (Rush et al., 2001; Fava et al., 2008) . A meta-analysis of data from 10 double-blind RCTs did not find a difference in response to treatment with SSRIs versus bupropion for depression or anxiety symptoms (Papakostas et al., 2008) . Randomized trials in suicidal patients are few, and none of the aforementioned studies investigated suicidal ideation as an outcome.
The results of this study should be interpreted with the following limitations in mind. The study lacked an anxiety scale, but the HDRS anxiety symptom cluster used was systematically derived Keilp et al., 2012) and similar to other post-hoc study methods (Naslund et al., 2017) . Although baseline anxiety did not differ between groups, randomization was not stratified by anxiety severity. All models adjusted for baseline anxiety and baseline SSI scores. There was evidence of collinearity in the full model, so we focused on the reduced model and used bootstrapping for more rigorous P values. Given that patients with anxious depression were not specifically selected for, the generalizability of these findings to a wider clinical population must be considered. Patients presenting with comorbid axis I anxiety disorders and suicidal depression may respond differently from patients with anxiety symptoms as studied here. Additional limitations include the chance of false positives or negatives, as with any post-hoc analysis, and the relatively small sample size. Finally, patients with higher average SSI scores across the 8-week trial were more likely to miss visits (P = 0.032); however, the number of missed visits did not differ between treatment groups (P =0.115). The main strength of our study is that it is one of the relatively few RCTs to purposefully recruit depressed suicide ideators and attempters, and thus was enriched for the outcome of interest. Suicidal patients have often been excluded from clinical trials, limiting the evidence base for this population (Zimmerman et al., 2002) .
Conclusion
Federal Drug Administration approved medications for mood disorders take weeks to work, whereas suicidal patients need rapid relief. The American Psychiatric Association's guideline states, 'evidence for a lowering of suicide rates with antidepressant treatment is inconclusive' (Jacobs et al., 2003) , and the 26.5% increase in USA suicide rates from 1999 to 2015 (Centers for Disease Control and Prevention, 2017) underscores this gap in treatment. Depression predicts suicide attempts partly via its effect on suicidal ideation (Nock et al., 2010) . Our exploratory results find that higher ongoing anxiety correlates with higher suicidal ideation, irrespective of treatment. Future studies should examine possible stratification factors (e.g. trait anxiety vs. axis I anxiety disorders) that may affect this relationship, given the mixed results reported in the literature. The trend-level results, suggesting a moderating effect of baseline anxiety on treatment, generate a hypothesis that suicidal, depressed patients presenting with high anxiety may get faster relief of suicidal ideation with an SSRI compared with a noradrenergic medication. This possibility merits testing in a larger sample or existing data set.
